Screener
Neurocrine Biosciences NBIX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Stock-based compensation | 57.2 | 52.8 |
| Depreciation | 7.2 | 6.6 |
| Accretion of discount on available-for-sale debt securities, net | (1.3) | (4.6) |
| Amortization of acquired intangible assets | 0.1 | 1.0 |
| Changes in fair values of equity investments | (25.3) | 30.6 |
| Deferred income taxes | (61.1) | (13.7) |
| Non-cash lease expense | 2.7 | 7.2 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's accretion (amortization) of discounts and premiums, investments?
- Neurocrine Biosciences (NBIX) reported accretion (amortization) of discounts and premiums, investments of $1.3M in Q1 2026.
- How has Neurocrine Biosciences's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Neurocrine Biosciences's accretion (amortization) of discounts and premiums, investments decreased by 71.7% year-over-year, from $4.6M to $1.3M.
- What is the long-term trend for Neurocrine Biosciences's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's accretion (amortization) of discounts and premiums, investments has grown at a 14.5% compound annual growth rate (CAGR), from -$7.4M to $12.7M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the non-cash adjustment to net income resulting from the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the systematic recognition of the difference between the purchase price and the face value of investment securities over their remaining term. Investors use this to reconcile reported net income with actual cash flows generated from the company's investment portfolio.
Ask your AI about Neurocrine Biosciences's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude